Clinical Trials Browser

Esophageal Neoplasms, Stomach Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Gastroesophageal Adenocarcinoma

Adenocarcinoma, Rectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Neoplasms, Meningeal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Stomach Neoplasms

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Esophageal Neoplasms

Stomach Neoplasms

HER2-positive Early Breast Cancer

Salivary Gland Neoplasms

Cancer Related Cognitive Decline

Colonic Neoplasms

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Colonic Neoplasms

Rectal Neoplasms, Stomach Neoplasms

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

HER2-positive Breast Cancer

Breast Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Biliary Tract Neoplasms

Breast Neoplasms, Heart Failure

HER2-positive Breast Cancer

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms, Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Stomach Neoplasms

HER2-positive Advanced Gastric Cancer

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Pathologic Complete Response, Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Clinical Trials

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

I-SPY

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

A Study of Surgery and Radiotherapy in People With Breast Cancer

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

TAPUR

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

ROSETTE

TAYLOR

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

RAGE

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

TRIFLUOX-DP

DETERMINE

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

ARIADNE

The Sagittarius Trial

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

TRAP-BTC

ProTarget

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

BRE-10

TAB-2

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

MINUTE

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

SAFIR-ABC10

SCHOLAR-2

TUC-TOC

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

RESPONSE

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

TREAZURE

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

IRIS

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).